Paper46388
Advanced diffuse histiocytic lymphoma, a potentially curable disease.
DeVita VT and 5 others. Lancet, 1975. Cited by 509 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Papers, record 46388. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/46388
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Administration, Oral | |
| Adult | |
| Aged | |
| Biopsy | |
| Cyclophosphamide | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Nitrogen Mustard Compounds | |
| Prednisone | |
| Procarbazine | |
| Remission, Spontaneous | |
| Time Factors | |
| Vincristine |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | Background |
Source ClinicalTrials.gov
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 509 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,747,191 | Persistence of PET scan positivity after chemoimmunotherapy for DLBCL. | Blood Adv | 2026 | https://conductscience.org/library/papers/41747191 | PubMed |
| 39,993,179 | A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma. | Blood Cancer Discov | 2025 | https://conductscience.org/library/papers/39993179 | PubMed |
| 39,049,984 | Quality of life assessment and cost‑utility analysis of initial chemotherapy for patients with non‑Hodgkin's lymphoma: A prospective analysis. | Oncol Lett | 2024 | https://conductscience.org/library/papers/39049984 | PubMed |
| 38,328,609 | Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018). | Cancer Pathog Ther | 2023 | https://conductscience.org/library/papers/38328609 | PubMed |
| 34,807,015 | DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? | Clin Adv Hematol Oncol | 2021 | https://conductscience.org/library/papers/34807015 | PubMed |
| 33,466,277 | NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33466277 | PubMed |
| 32,496,453 | Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. | Cancer J | 2020 | https://conductscience.org/library/papers/32496453 | PubMed |
| 29,531,285 | Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. | Blood Cancer J | 2018 | https://conductscience.org/library/papers/29531285 | PubMed |
| 28,683,298 | Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. | Cell Metab | 2017 | https://conductscience.org/library/papers/28683298 | PubMed |
| 27,568,520 | Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. | Leukemia | 2017 | https://conductscience.org/library/papers/27568520 | PubMed |
| 26,969,332 | Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort. | Eur J Health Econ | 2017 | https://conductscience.org/library/papers/26969332 | PubMed |
| 26,355,399 | A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma. | Sultan Qaboos Univ Med J | 2015 | https://conductscience.org/library/papers/26355399 | PubMed |
| 26,248,897 | Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. | Mod Pathol | 2015 | https://conductscience.org/library/papers/26248897 | PubMed |
| 25,501,975 | Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. | Ann Hematol | 2015 | https://conductscience.org/library/papers/25501975 | PubMed |
| 24,338,592 | Modelling lymphoma therapy and outcome. | Bull Math Biol | 2014 | https://conductscience.org/library/papers/24338592 | PubMed |
| 24,217,204 | Diffuse large B-cell lymphoma-treatment approaches in the molecular era. | Nat Rev Clin Oncol | 2014 | https://conductscience.org/library/papers/24217204 | PubMed |
| 24,212,956 | Assessment of the evolution of cancer treatment therapies. | Cancers (Basel) | 2011 | https://conductscience.org/library/papers/24212956 | PubMed |
| 23,086,603 | Diffuse large B cell lymphoma: molecular targeted therapy. | Int J Hematol | 2012 | https://conductscience.org/library/papers/23086603 | PubMed |
| 22,305,028 | My treatment approach to patients with diffuse large B-cell lymphoma. | Mayo Clin Proc | 2012 | https://conductscience.org/library/papers/22305028 | PubMed |
| 20,011,310 | Colorectal lymphoma. | Clin Colon Rectal Surg | 2006 | https://conductscience.org/library/papers/20011310 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/46388
GET https://conductscience.org/api/papers/v1/46388/cited_by?page=2